Climb Bio (NASDAQ:CLYM) Price Target Raised to $18.00

Climb Bio (NASDAQ:CLYM) had its price target boosted by Oppenheimer from $10.00 to $18.00 in a research report report published on Tuesday,Benzinga reports. They currently have an outperform rating on the stock.

Other equities analysts also recently issued reports about the company. Robert W. Baird lifted their target price on Climb Bio from $9.00 to $12.00 and gave the company an “outperform” rating in a research report on Friday, March 6th. Piper Sandler initiated coverage on Climb Bio in a research report on Friday, February 13th. They issued an “overweight” rating for the company. BTIG Research reissued a “buy” rating and set a $8.00 price objective on shares of Climb Bio in a research report on Wednesday, April 8th. Weiss Ratings reissued a “sell (d-)” rating on shares of Climb Bio in a research report on Wednesday, January 21st. Finally, Raymond James Financial initiated coverage on Climb Bio in a research report on Tuesday, March 10th. They set a “strong-buy” rating and a $25.00 price objective for the company. Three equities research analysts have rated the stock with a Strong Buy rating, eight have assigned a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, Climb Bio presently has a consensus rating of “Buy” and a consensus price target of $16.78.

Climb Bio Price Performance

NASDAQ CLYM opened at $9.02 on Tuesday. The company has a market cap of $430.89 million, a P/E ratio of -10.13 and a beta of -0.21. The stock has a 50-day moving average of $7.20 and a two-hundred day moving average of $4.57. Climb Bio has a 1-year low of $1.13 and a 1-year high of $10.00.

Climb Bio (NASDAQ:CLYM) last released its earnings results on Thursday, March 5th. The company reported ($0.26) earnings per share for the quarter, missing the consensus estimate of ($0.20) by ($0.06). On average, analysts anticipate that Climb Bio will post -1.11 EPS for the current fiscal year.

Hedge Funds Weigh In On Climb Bio

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. Peapod Lane Capital LLC grew its position in shares of Climb Bio by 0.7% during the fourth quarter. Peapod Lane Capital LLC now owns 565,992 shares of the company’s stock worth $2,264,000 after buying an additional 4,126 shares in the last quarter. XTX Topco Ltd lifted its stake in Climb Bio by 19.4% during the fourth quarter. XTX Topco Ltd now owns 34,852 shares of the company’s stock worth $139,000 after purchasing an additional 5,668 shares during the last quarter. Virtu Financial LLC purchased a new stake in Climb Bio during the fourth quarter worth approximately $43,000. Blair William & Co. IL purchased a new stake in Climb Bio during the fourth quarter worth approximately $44,000. Finally, Hsbc Holdings PLC lifted its stake in Climb Bio by 107.2% during the fourth quarter. Hsbc Holdings PLC now owns 24,744 shares of the company’s stock worth $99,000 after purchasing an additional 12,800 shares during the last quarter. 69.76% of the stock is owned by institutional investors and hedge funds.

About Climb Bio

Climb Bio Therapeutics, Inc is a clinical-stage biotechnology company focused on the discovery and development of engineered protein therapeutics for the treatment of cancer and immune-mediated disorders. The company’s mission centers on designing biologics with enhanced specificity and functional activity to engage key cellular targets and improve patient outcomes in areas of high unmet need.

At the heart of Climb Bio’s approach is its proprietary protein engineering platform, which combines mammalian cell display, directed evolution and computational modeling.